Prior to 2012
Pamela Vig, PhD Joins Presidio Pharmaceuticals as Senior Director of Clinical Research
San Francisco, CA – June 2, 2010 – Presidio Pharmaceuticals, Inc. is pleased to announce that Pamela Vig, Ph.D. has joined the company as Senior Director of Clinical Research.
“Pam’s extensive background in antiviral drug development is an important boost to our clinical development programs,” said Nathaniel Brown, M.D., Chief Medical Officer. “As we enter into a series of clinical trials for our lead hepatitis C virus (HCV) NS5A inhibitor, PPI-461, Pam’s expertise will be of great value to optimizing the design and conduct of our clinical trial programs. We are very pleased to have Pam join us to further build Presidio’s drug development capacity.” PDF
Eric Ruby Joins Presidio Pharmaceuticals as Vice President of Regulatory Affairs
San Francisco, CA – January 12, 2010 – Presidio Pharmaceuticals, Inc. is pleased to announce that Eric Ruby has joined the Company as Vice President of Regulatory Affairs.
“The addition of Eric to our team significantly contributes to Presidio’s clinical development of our NS5A inhibitor in 2010,” said Omar Haffar, Founder, President and Chief Executive Officer. “Eric’s extensive background in regulatory affairs will enhance and complement Presidio’s existing management team and strengthen our ability to create value for the company and our investors. All of us at Presidio look forward to working with Eric and to maintaining our pace of building a vibrant drug development organization.”PDF
Dr. Nathaniel Brown Joins Presidio Pharmaceuticals as SVP of Clinical Development
San Francisco, CA – August 5, 2009 – Presidio Pharmaceuticals, Inc. is pleased to announce that Dr. Nathaniel Brown has joined the Company as Senior Vice President of Clinical Development.
“Nat has had a stellar career and brings to the Company a wealth of experience and expertise in the clinical development of small molecule therapeutics for treating patients with HCV, HBV and HIV” said Omar Haffar, President and CEO. “Having Nat join Presidio’s management team as we work toward clinical development of our NS5A clinical candidate for treating HCV is a great achievement for us. I look forward to working with Nat and the rest of the team in building a strong and integrated Company”. PDF
Leo Redmond Joins Presidio Pharmaceuticals As Chief Financial Officer
San Francisco, CA – January 7, 2008 – Presidio Pharmaceuticals, Inc. announced today the appointment of Mr. Leo Redmond to the position of Chief Financial Officer. Mr. Redmond brings 20 years of financial experience to Presidio. PDF
Presidio Pharmaceuticals Relocates To San Francisco’s Mission Bay Campus
San Francisco, CA – December 5, 2007 – Presidio Pharmaceuticals, Inc. announced today that it has relocated its corporate headquarters to San Francisco’s Mission Bay campus.
The new headquarters, located at 1700 Owens Street in San Francisco’s Mission Bay District, is within a new office/lab complex developed by Alexandria Real Estate Equities. PDF
Presidio Pharmaceuticals Adds Industry Veteran Dr. Richard Colonno as Chief Scientific Officer
San Francisco, CA – September 18, 2007 – Presidio Pharmaceuticals, Inc. announces today that internationally recognized virologist and antiviral drug discoverer Dr. Richard Colonno has joined the company as Chief Scientific Officer. PDF